Cetera Investment Advisers Intellia Therapeutics, Inc. Transaction History
Cetera Investment Advisers
- $55.9 Billion
- Q2 2025
A detailed history of Cetera Investment Advisers transactions in Intellia Therapeutics, Inc. stock. As of the latest transaction made, Cetera Investment Advisers holds 33,532 shares of NTLA stock, worth $319,224. This represents 0.0% of its overall portfolio holdings.
Number of Shares
33,532
Previous 22,747
47.41%
Holding current value
$319,224
Previous $161,000
95.03%
% of portfolio
0.0%
Previous 0.0%
Shares
11 transactions
Others Institutions Holding NTLA
# of Institutions
339Shares Held
97.2MCall Options Held
1.66MPut Options Held
1.05M-
Cathie Wood Ark Investment Management LLC | St. Petersburg, Fl13MShares$124 Million1.01% of portfolio
-
Vanguard Group Inc Valley Forge, PA11MShares$105 Million0.0% of portfolio
-
Black Rock Inc. New York, NY9.6MShares$91.4 Million0.0% of portfolio
-
Morgan Stanley New York, NY4.12MShares$39.2 Million0.0% of portfolio
-
State Street Corp Boston, MA4.04MShares$38.5 Million0.0% of portfolio
About Intellia Therapeutics, Inc.
- Ticker NTLA
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 76,011,800
- Market Cap $724M
- Description
- Intellia Therapeutics, Inc., a genome editing company, focuses on the development of therapeutics. The company's in vivo programs include NTLA-2001, which is in Phase 1 clinical trial for the treatment of transthyretin amyloidosis; and NTLA-2002 for the treatment of hereditary angioedema, as well as other liver-focused programs comprising hemoph...